Publications

Publications

The Future of NMR Metabolomics in Cancer Therapy: Towards Personalizing Treatment and Developing Targeted Drugs?

By:
Contributors: Hans Vogel Research Group
Metabolites. 2013 May 17;3(2):373-96. doi: 10.3390/metabo3020373.

Abstract

There has been a recent shift in how cancers are defined, where tumors are no longer simply classified by their tissue origin, but also by their molecular characteristics. Furthermore, personalized medicine has become a popular term and it could start to play an important role in future medical care. However, today, a “one size fits all” approach is still the most common form of cancer treatment. In this mini-review paper, we report on the role of nuclear magnetic resonance (NMR) metabolomics in drug development and in personalized medicine. NMR spectroscopy has successfully been used to evaluate current and potential therapies, both single-agents and combination therapies, to analyze toxicology, optimal dose, resistance, sensitivity, and biological mechanisms. It can also provide biological insight on tumor subtypes and their different responses to drugs, and indicate which patients are most likely to experience off-target effects and predict characteristics for treatment efficacy. Identifying pre-treatment metabolic profiles that correlate to these events could significantly improve how we view and treat tumors. We also briefly discuss several targeted cancer drugs that have been studied by metabolomics. We conclude that NMR technology provides a key platform in metabolomics that is well-positioned to play a crucial role in realizing the ultimate goal of better tailored cancer medicine.

 

PubMed

Download PDF

 

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

APCaRI Fall Symposium Oct. 26 to 27, 2018, Banff, Alberta

2018 APCaRI Fall Symposium – Knowledge, Action, Impact

On October 26 – 27, 2018 APCaRI will celebrate its 11th research meeting at the Banff Park Lodge, in Banff, Alberta. Previous fall symposia have had over 60 participants participating in this fun and enriching event, including clinicians, scientists, clinical research personnel, trainees, benefactors and representatives of PCa support groups. Plan on attending the 2018 Fall symposium to discuss and share ideas and enjoy the beautiful Rockies!

Please submit your abstracts to Rume at djebah@ualberta.ca. Please let Rume know as soon as possible if you cannot attend. The APCaRI Fall symposium is generously supported by the Alberta Cancer Foundation and its’ donors

Dates to remember:

Trainee abstract submission deadline is September 10

Registration deadline is September 14

Submit abstracts to djebah@ualberta.ca.

APCaRI Fall symposium site- Banff Park Lodge
Banff Park Lodge

 

 

- Unknown